Syndex Bio, a biotechnology company advancing next‑generation molecular diagnostics, has announced the introduction of its proprietary mcPCR (methyl‑copying PCR) platform at the Advances in Genome Biology and Technology (AGBT) conference in Orlando, Florida.
mcPCR enables ‘PCR for methylation’, the high-fidelity copying of both DNA methylation and the four-base genetic code during DNA amplification. This overcomes a fundamental limitation of PCR, which cannot amplify DNA methylation patterns that are critical for the detection of many diseases, including cancer. By enabling simpler, faster and more sensitive analysis of methylated DNA, mcPCR will help to transform the testing of clinical samples, especially in non-invasive and small-sample biopsies for early disease detection and recurrence monitoring.
Syndex Bio also announced the successful close of an oversubscribed $15.5 million seed financing led by ARCH Venture Partners, with participation from +ND Capital, OMX Ventures, and Meltwind. The funds will support expansion of the mcPCR platform, development of clinical workflows and applications, and build‑out of the company’s R&D footprint in Cambridge, UK.
“Syndex Bio’s mcPCR platform makes amplifying DNA methylation possible for the first time. This powerful method will redefine the sensitivity and accuracy that is achievable in DNA methylation analysis, opening new possibilities for early detection and disease monitoring,” said Geoff Smith, PhD, Founder and CEO of Syndex Bio. “We’re honoured to have the support of world‑class investors and advisors as we advance toward clinical translation.”
The company’s Founder and CEO, Geoff Smith PhD, will present a poster (#470) titled mcPCR: PCR For Methylation at the AGBT General Meeting from 23–26 February 2026. Copies of the poster will also be available to download from Syndex Bio’s website.
For further information about Syndex Bio’s mcPCR platform technology and its team, please visit: www.syndex.bio.